Sutro Biopharma (STRO) Competitors $0.76 -0.01 (-0.77%) Closing price 04:00 PM EasternExtended Trading$0.77 +0.01 (+1.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. CADL, ACB, IMMP, CRDF, FENC, SLRN, MNPR, PRQR, NBTX, and TVGNShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Candel Therapeutics (CADL), Aurora Cannabis (ACB), Prima BioMed (IMMP), Cardiff Oncology (CRDF), Adherex Technologies (FENC), Acelyrin (SLRN), Monopar Therapeutics (MNPR), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Candel Therapeutics Aurora Cannabis Prima BioMed Cardiff Oncology Adherex Technologies Acelyrin Monopar Therapeutics ProQR Therapeutics Nanobiotix Semper Paratus Acquisition Candel Therapeutics (NASDAQ:CADL) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership. Which has more volatility and risk, CADL or STRO? Candel Therapeutics has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Does the media prefer CADL or STRO? In the previous week, Candel Therapeutics had 7 more articles in the media than Sutro Biopharma. MarketBeat recorded 7 mentions for Candel Therapeutics and 0 mentions for Sutro Biopharma. Candel Therapeutics' average media sentiment score of 1.16 beat Sutro Biopharma's score of 0.96 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Candel Therapeutics Positive Sutro Biopharma Positive Do institutionals & insiders hold more shares of CADL or STRO? 13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 16.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate CADL or STRO? Candel Therapeutics presently has a consensus price target of $22.00, suggesting a potential upside of 226.41%. Sutro Biopharma has a consensus price target of $6.11, suggesting a potential upside of 704.51%. Given Sutro Biopharma's higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Candel Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Sutro Biopharma 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has stronger earnings and valuation, CADL or STRO? Candel Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Candel Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K2,813.95-$55.18M-$1.34-5.03Sutro Biopharma$62.04M1.03-$227.46M-$2.98-0.26 Is CADL or STRO more profitable? Candel Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -373.66%. Candel Therapeutics' return on equity of -136.74% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -136.74% -63.13% Sutro Biopharma -373.66%-347.60%-59.46% SummaryCandel Therapeutics beats Sutro Biopharma on 11 of the 17 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.69M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-0.268.2821.0120.09Price / Sales1.03303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book1.417.678.125.65Net Income-$227.46M-$55.28M$3.25B$257.91M7 Day Performance-0.20%2.50%0.97%2.09%1 Month Performance-4.26%11.70%7.36%11.13%1 Year Performance-79.57%4.89%31.31%18.40% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma4.2057 of 5 stars$0.76-0.8%$6.11+704.5%-81.1%$64.69M$62.04M-0.26240CADLCandel Therapeutics2.518 of 5 stars$4.99-2.2%$22.00+340.9%+5.3%$250.00M$120K-3.7260Positive NewsACBAurora Cannabis0.3883 of 5 stars$4.43-2.4%N/A-23.4%$249.01M$246.72M40.271,130IMMPPrima BioMed1.5303 of 5 stars$1.68-2.3%$7.00+316.7%-15.5%$245.35M$5.14M0.002,021Gap UpCRDFCardiff Oncology1.2919 of 5 stars$3.65-0.3%$9.88+170.5%+75.2%$242.83M$680K-3.9720FENCAdherex Technologies2.2886 of 5 stars$8.47-3.8%$13.00+53.5%+31.6%$233.77M$47.54M-16.6110SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135MNPRMonopar Therapeutics2.4252 of 5 stars$37.20+2.6%$60.00+61.3%+1,231.0%$227.66MN/A-10.6910News CoverageInsider TradePRQRProQR Therapeutics2.6141 of 5 stars$2.14-1.8%$8.00+273.8%+30.8%$225.15M$20.46M-6.11180NBTXNanobiotix2.6844 of 5 stars$4.75-2.5%$8.00+68.6%-1.9%$223.68M$39.18M0.00100TVGNSemper Paratus Acquisition4.1066 of 5 stars$1.20-3.2%$10.00+733.3%+69.9%$220.67MN/A0.003News Coverage Related Companies and Tools Related Companies Candel Therapeutics Alternatives Aurora Cannabis Alternatives Prima BioMed Alternatives Cardiff Oncology Alternatives Adherex Technologies Alternatives Acelyrin Alternatives Monopar Therapeutics Alternatives ProQR Therapeutics Alternatives Nanobiotix Alternatives Semper Paratus Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
